Drug Trial Radar · NCT00943111
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)
Last checked: Nov 19, 2026Latest source record: Nov 25, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
160
Actual
Start
Sep 2009
Primary completion
Nov 2012
Study completion Jun 2015
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jul 22, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 study was designed to confirm the efficacy and safety of eliglustat tartrate (Genz-112638) in participants with Gaucher disease type 1 who had reached therapeutic goals with enzyme replacement therapy (ERT).
Conditions
- Gaucher Disease, Type 1
Interventions
Eliglustat tartrateDrug
Primary analysis period (PAP): Eliglustat tartrate capsule 50 milligram (mg) twice daily (BID) orally from Day 1 to Week 4 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 8, and then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 52. Dose adjustments after Week 4 and Week 8 were based on Genz-99067 (active moiety of eliglustat tartrate in plasma) trough plasma concentrations. If Genz-99067 trough plasma concentration was less than (\<) 5 nanogram per milliliter \[ng/mL\] next higher dose was administered whereas if Genz-99067 trough plasma concentration was greater than or equal to (\>=) 5 ng/mL same dose was continued. Pharmacokinetic (PK) assessment at Week 2 and 6 were used for dose adjustment after Week 4 and Week 8, respectively. Long-term treatment period (LTTP): Participants originally randomized to eliglustat in PAP continued to receive eliglustat dose, based on their Genz 99067 plasma trough concentration at Week 6.
ImigluceraseDrug
PAP: Imiglucerase intravenous infusion every other week (q2w) up to Week 52 in doses equivalent to participant's past ERT dose prior to any unanticipated treatment interruption, dose reduction, or regimen change. LTTP: Participants originally randomized to imiglucerase received eliglustat tartrate capsule 50 mg BID orally from Week 52+1 Day to Week 56 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 60, and then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to 5 years. The dose adjustments after Week 56 and Week 60 were based on Genz-99067 (active moiety of eliglustat tartrate in plasma) trough plasma concentrations. If Genz-99067 trough plasma concentration was \<5 ng/mL the next higher dose was administered whereas if the Genz-99067 trough plasma concentration was \>=5 ng/mL the same dose was continued. The PK assessment at Week 54 and Week 58 were used for dose adjustment after Week 56 and Week 60, respectively.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Remained Stable for 52 Weeks During the Primary Analysis PeriodTime frame: Baseline up to Week 52
- Percentage of Participants Who Remained Stable Annually for 4 Years During the LTTPTime frame: Week 52 up to week 208
Locations
34 sites in 12 countries. Site status is shown where the registry gives one.
Tower Hematology Oncology Medical Group
Beverly Hills, California
UCSF MS Center
San Francisco, California
University of Colorado Health Science Center - Aurora
Aurora, Colorado
Yale University School of Medicine
New Haven, Connecticut
Northwest Oncology Hematology Associates PA
Coral Springs, Florida
Emory University Medical Genetics
Decatur, Georgia
Children's Memorial Hospital
Chicago, Illinois
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Albany Medical Center
Albany, New York
North Shore University Medical Center
Manhasset, New York
Mount Sinai School of Medicine
New York, New York
New York University School of Medicine
New York, New York
Duke University Medical Center
Durham, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
O and O Alpan LLC
Springfield, Virginia
Hospital General de Agudos J.M Ramos Mejia
Buenos Aires, Argentina
Hospital General de Ninos Dr. Ricardo Gutierrez
Buenos Aires, Argentina
Royal Perth Hospital
Perth, WA, Australia
Hospital de Clinicas da Universidade Federal do Parana
Curitiba, Brazil
Instituto de Estadual de Hematologia Arthur de Siqueria Cavalcanti
Rio de Janeiro, Brazil
IGEIM
São Paulo, Brazil
Mount Sinai Hospital and the Samuel Lunenfeld Research Institute
Toronto Ontario, Canada
Abou El Reesh Children's University Hospital (El Mounira), Faculty of Medicine (Kasr Al-Aini), Cairo University Hospitals, El Mounira, Cairo, Egypt
Cairo, Egypt
Hôpital Beaujon
Clichy, France
Charité Universitätsmedizin Berlin
Berlin, Germany
Asklepios Klinik St. Georg
Hamburg, Germany
Katholische Kliniken Oberhausen gem. GmbH
Oberhausen, Germany
Azienda Ospedaliero Universitaria Careggi
Florence, Italy
Azienda Ospedialiero-Universitaria S. Maria Della Misericordia
Udine, Italy
Hematology Research Center of Ministry of Healthcare of the Russian Federation
Moscow, Russia
Hospital University Miguel Servet
Zaragoza, Spain
Cambridge University Hosptials, Addenbrookes Hospital
Cambridge, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.